Thus, in this specific population of RA patients treated with tocilizumab or possibly other anti-rheumatic drugs, as we reported for an anti-TNF agent [16], LDL increase should not be automatically interpreted as proatherogenic, due to the favorable changes in LDL function. The gene discussed is TNF; the disease is rheumatoid arthritis.